Amphastar Pharmaceuticals (AMPH) Gross Margin (2013 - 2026)

Amphastar Pharmaceuticals has reported Gross Margin for 14 years, with the latest figure at 50.83% in Q2 2026.

• On a quarterly basis, Gross Margin rose 124.0% year-over-year to 50.83% in Q2 2026; TTM through Jun 2026 was 47.68%, a 218.0% decrease from a year earlier, with the FY2025 full-year figure at 49.46%, down 162.0% from the prior year.
• Gross Margin was 50.83% for Q2 2026 at Amphastar Pharmaceuticals, up from 41.08% in the prior quarter.
• The five-year high for Gross Margin was 60.04% in Q3 2023, with the low at 41.08% in Q1 2026.
• Average Gross Margin over 5 years is 50.55%, with a median of 51.07% recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Gross Margin surged 1133 bps in 2023, then sank 891 bps in 2026.
• Over 5 years, Gross Margin stood at 52.71% in 2022, then increased by 2 bps to 53.98% in 2023, then retreated by 14 bps to 46.45% in 2024, then grew by 1 bps to 46.79% in 2025, then climbed by 9 bps to 50.83% in 2026.
• The last three Gross Margin figures came in at 50.83% (Q2 2026), 41.08% (Q1 2026), and 46.79% (Q4 2025), per Business Quant data.